Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary effusion lymphoma: current concepts and management.

Nivedita Arora1, Arjun Gupta, Navid Sadeghi

  • 1aDepartment of Internal Medicine bDivision of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Current Opinion in Pulmonary Medicine
|April 12, 2017
PubMed
Summary

Primary effusion lymphoma (PEL) is an aggressive cancer mainly affecting HIV-positive men. Current treatments lack randomized trials, and prognosis remains poor, necessitating further research into optimal strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of low-dose immune checkpoint inhibitors in low- and middle-income countries: a national survey of oncologists and hematologists in Mexico.

Ecancermedicalscience·2026
Same author

Patient, care partner, and oncologist perspectives on clinically important survival thresholds after considering time toxicity in advanced cancer.

The oncologist·2026
Same author

Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

Breast cancer research and treatment·2026
Same author

Power wheelchair vendors: Declines in rural market activity.

Disability and health journal·2026
Same author

Healthcare contact days in cancer survivors relative to those with no cancer history.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Cluster analysis identifies high-risk phenotypic groups for revision following 1-3 level lumbar fusion in a disadvantaged inner-city population.

North American Spine Society journal·2026

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Primary effusion lymphoma (PEL) is an aggressive B-cell neoplasm associated with immunosuppression, particularly in HIV-positive individuals.
  • PEL classically presents as effusions in body cavities and is linked to human herpesvirus-8 (HHV-8).
  • Risk factors include HIV infection, advanced age, cirrhosis, and organ transplantation.

Purpose of the Study:

  • To review the current epidemiology, management, and outcomes of primary effusion lymphoma (PEL).
  • To identify potential future research directions for PEL.

Main Methods:

  • Review of current literature on PEL epidemiology, treatment, and outcomes.
  • Analysis of treatment strategies including chemotherapy, immunomodulatory agents, proteasome inhibitors, and targeted therapies.

Related Experiment Videos

  • Emphasis on the role of highly active antiretroviral therapy (HAART) in HIV-infected patients.

    • Main Results:

    • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy is a common treatment, often combined with other agents.
    • HAART is crucial for HIV-positive PEL patients.
    • The rarity of PEL limits the availability of randomized controlled trials, contributing to a grim prognosis.

    Conclusions:

    • Optimal treatment strategies for PEL require further investigation due to a lack of randomized controlled trials.
    • Advances in understanding HHV-8 oncogenic pathways may lead to novel targeted therapies.
    • There is a critical need for improved therapeutic approaches to improve outcomes for PEL patients.